Navigation Links
Potential therapy discovered for hypophosphatasia, a congenital form of rickets
Date:5/30/2008

Researchers at the Burnham Institute for Medical Research, led by Jos Luis Milln, Ph.D., have demonstrated in mice the first successful use of enzyme replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal disease of genetic origin. This discovery lays the foundation for future clinical trials for HPP patients.

Rickets is a softening of the bones that most commonly results from a lack of vitamin D or calcium and from insufficient exposure to sunlight. Hypophosphatasia is a rare, heritable form of rickets caused by mutations in a gene called TNAP, which is essential for the process that causes minerals such as calcium and phosphorus to be deposited in developing bones and teeth. The physical presentations of this disorder can vary depending on the specific mutation, with more severe symptoms occurring at a younger age of onset. The most severe form of the disease occurs at birth, which can present with absence of bone mineralization in utero, resulting in stillbirth.

Using a mouse model, Jos Luis Milln, Ph.D. tested the hypothesis that, when administered from birth, a bone-targeted form of the TNAP gene would ease the skeletal defects of HPP. The Milln laboratory, in collaboration with scientists from Enobia Pharma in Montreal, Canada and from the Shriners Hospitals for Children in St. Louis, Missouri, created a soluble form of human TNAP that had been shown to display a strong attraction to bone tissue. Upon injecting the enzyme into the fat layer under the skin of the mice, the treated mice maintained a healthy rate of growth and apparent well being, as well as normal bone mineral density (BMD) of the skull, femur and spine. In fact, complete preservation of skeletal and dental structures were observed after 15 days, and bone lesions were still not seen after 52 days of treatment.

"While the biochemical mechanism that leads to skeletal and dental defects of HPP is now generally understood," said Dr
'/>"/>

Contact: Andrea Moser
amoser@burnham.org
858-646-3146
Burnham Institute
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Compound has potential for new class of AIDS drugs
2. Finding the real potential of no-till farming for sequestering carbon
3. Biomarker predicts malignancy potential of HG-PIN lesions in the prostate
4. In computer models and observations, researchers see potential for significant red tide season
5. Menstrual blood -- a valuable source of multipotential stem cells?
6. Forests long-term potential for carbon offsetting
7. Scientists uncover the potential to control adult stem cells
8. Cold Spring Harbor Laboratory scientists devise potential approach to treat spinal muscular atrophy
9. Researchers to develop ocean sanctuary noise budget to evaluate potential impact on marine mammals
10. Potential association of type 2 diabetes genes with prostate cancer
11. Potential new target for multiple sclerosis therapy

Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Potential therapy discovered for hypophosphatasia, a congenital form of rickets
Potential therapy discovered for hypophosphatasia, a congenital form of rickets
(Date:11/20/2009)...er 19, 2009 The estimated 4.6 million Americans i...eveloping respiratory symptoms due to poor air qua...study undertaken earlier this year by investigator...ary Medicine. , The studywhich polled more than ...cent of individuals working in barns complained of...
(Date:11/20/2009)...n German . , In the current online issue of...anie Eyerich and Dr. Kilian Eyerich together with ...Istituto Dermopatico dell,Immacolata in Rome, pres...a milestone on the way to developing new treatment...oriasis and allergic reactions and potentially als...
(Date:11/20/2009)...udy, researchers report that a class of heart medi...r harmful, effect on the heart, depending on their...in the journal Circulation Research , found that ...-receptors on the heart muscle offer the most bene...nly the beta-receptors can actually undermine the ...
Breaking Biology News(10 mins):Barn personnel experience higher-than-average rates of respiratory symptoms 2Discovery of new type of immune cells regulating inflammation in chronic diseases 2Carvedilol shown to have unique characteristics among beta blockers 2Promising medical trainees receive funding to pursue research in hematology 51518 1Promising medical trainees receive funding to pursue research in hematology 51518 2American Society of Hematology awards grants to encourage novel medical training programs 51514 1American Society of Hematology awards grants to encourage novel medical training programs 51514 2Bausch 26 Lomb Receives Approval of Crystalens HD in Quarter Diopter Steps 51511 1Bausch 26 Lomb Receives Approval of Crystalens HD in Quarter Diopter Steps 51511 2Bausch 26 Lomb Receives Approval of Crystalens HD in Quarter Diopter Steps 51511 3
...tists has discovered three molecules –?from a sear...key perpetrator of Alzheimer,s disease. , Each of ...au," which becomes hopelessly tangled in the brain...mising news for the development of drugs for the d...nce Research Institute at the University of Califo...
... tsunami that killed over a quarter of a million p...004, slowly disappear from the media, but the even... of those who are directly involved. In the afterm...ke are trying to investigate how the number of cas...t, how such severe damage can be avoided if a tsun...
...tists has discovered three molecules –?from a sear...key perpetrator of Alzheimer,s disease. , Each of ...au," which becomes hopelessly tangled in the brain...mising news for the development of drugs for the d...nce Research Institute at the University of Califo...
Other Biology News:Scientists at Galileo Pharmaceuticals confirm inflammatory response linked to glucose levels 2Scientists at Galileo Pharmaceuticals confirm inflammatory response linked to glucose levels 3Could better mangrove habitats have spared lives in the 2004 tsunami? 2Scientists discover that three molecules may be developed into new Alzheimer's drugs 2Scientists discover that three molecules may be developed into new Alzheimer's drugs 3
(Date:11/19/2009)..., , COPENHAGEN, Nov. 19 Danis...nbicon cellulosic ethanol plant in Kalundborg, Den...ne of the world,s first and largest 2nd generation...ccellerase enzymes are used in the plant,s innovat..., a Division of Danisco, was the first to market w...
(Date:11/19/2009)..., , NEW YORK, Nov. 19 /PRNewswire-FirstCall/...day that it has sent the following letter to its s... on October 30, 2009, of China Biopharmaceuticals ...tical company based in the People,s Republic of Ch...terest in Suzhou Eyre Pharmaceutical Co. Ltd., CHB...
(Date:11/19/2009)..., , MONTREAL, Nov. 19 /PRNewswire/ - Aegera ...e first patient in a randomized Phase 2B study of ...stage development for multiple oncology indication...ized Phase 2 Study of the X-Linked Inhibitor of Ap...tion with High-dose Cytarabine and Idarubicin in A...
(Date:11/19/2009)..., , VIENNA, Austria, November 19 /PR... vaccine program on one product candidate at an un... candidate AD02 is planned to enter into,Phase II ... company,immediately follows the completion of two... The company based its fast decision on the first ...
Breaking Biology Technology:DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3
...ideo system , Optimized Imaging of Protein Gels... Michelle Cayouette Jane Moores ,Stratagene Clo...es an optical bandpass filter with all Eagle,Eye...sualizing,ethidium bromide fluorescence. However...dium bromide may be inadequate for use with other ...
... for robust, high-fidelity PCR,amplification ,...rie,Hedden Connie Hansen Janice Cline Frances ...ratagene , Stratagene announces the release of p...of Pfu DNA polymerase for high-fidelity,PCR. Pf...,polymerase and a novel thermostable factor that...
...chemiluminescent enhancer for increased sensitivit... (O 2 , ) , Danny Q. Hoang ,Stratagene ,...edicine, Dept. of Microbiology, Hanover, NH , St...y, a simple and unique chemiluminescent-based meth...oxide anions in cell culture. In addition, the kit...
Other Biology Technology:Optimized Imaging of Protein Gels Stained with Coomassie,Brilliant Blue Dye 2Optimized Imaging of Protein Gels Stained with Coomassie,Brilliant Blue Dye 3Optimized Imaging of Protein Gels Stained with Coomassie,Brilliant Blue Dye 4Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 2Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 3Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 4Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 5Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 6Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 7Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 8Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 9Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 10Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase 11Luminol-enhanced Assay for Superoxide Anion (O2 face="Symbol" ,) 2Luminol-enhanced Assay for Superoxide Anion (O2 face="Symbol" ,) 3Luminol-enhanced Assay for Superoxide Anion (O2 face="Symbol" ,) 4Luminol-enhanced Assay for Superoxide Anion (O2 face="Symbol" ,) 5
Mouse Anti-Kusabira Orange Monoclonal Antibody, Unconjugated, Clone 2G9 from MBL International
Goat Anti-SPFH2 Polyclonal Antibody, Unconjugated from Abcam
Goat Anti-Als2 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Kusabira Orange Monoclonal Antibody, Unconjugated, Clone 2G9 from MBL International
Biology Products: